Greater Trochanteric Pain Syndrome
Greater Trochanteric Pain Syndrome (GTPS), characterized by pain and tenderness over the greater trochanter of the femur, is a prevalent musculoskeletal disorder affecting individuals across various age groups. According to the National Institutes of Health (NIH) in the United States, GTPS has significant societal and economic impacts (source: National Institutes of Health, NIH).
GTPS is highly prevalent, particularly among middle-aged and older adults. The Institute for Health Metrics and Evaluation (IHME) at the University of Washington, in collaboration with the Global Burden of Disease Study, reports that musculoskeletal conditions, including GTPS, contribute substantially to disability worldwide. In industrialized nations, the lifetime prevalence of GTPS can exceed 50%, significantly impacting work productivity and healthcare costs (source: Institute for Health Metrics and Evaluation (IHME), University of Washington).
The development of GTPS is associated with several risk factors, such as age, gender, obesity, and specific physical activities. Female gender, previous hip injuries, and occupations involving repetitive hip movements or prolonged sitting are recognized risk factors (source: Cochrane Database of Systematic Reviews). Diagnosis primarily relies on clinical assessment, with imaging studies used to exclude other potential causes of hip pain.
GTPS is highly prevalent, particularly among middle-aged and older adults. The Institute for Health Metrics and Evaluation (IHME) at the University of Washington, in collaboration with the Global Burden of Disease Study, reports that musculoskeletal conditions, including GTPS, contribute substantially to disability worldwide. In industrialized nations, the lifetime prevalence of GTPS can exceed 50%, significantly impacting work productivity and healthcare costs (source: Institute for Health Metrics and Evaluation (IHME), University of Washington).
The development of GTPS is associated with several risk factors, such as age, gender, obesity, and specific physical activities. Female gender, previous hip injuries, and occupations involving repetitive hip movements or prolonged sitting are recognized risk factors (source: Cochrane Database of Systematic Reviews). Diagnosis primarily relies on clinical assessment, with imaging studies used to exclude other potential causes of hip pain.
PerVitaShockNavi™
.jpeg?w=1420&h=800)
Treatment Position
For extracorporeal shockwave therapy (ESWT) in the treatment of GTPS, patient positioning varies based on the specific therapy and the practitioner's preference. Common positions include lateral recumbency or sitting to facilitate access to the affected area over the greater trochanter (source: British Pain Society guidelines).
-
PerVitaShockNavi™
Treatment Position
For extracorporeal shockwave therapy (ESWT) in the treatment of GTPS, patient positioning varies based on the specific therapy and the practitioner's preference. Common positions include lateral recumbency or sitting to facilitate access to the affected area over the greater trochanter (source: British Pain Society guidelines).
.jpeg?w=1420&h=800)
Localization Method
The localization of the treatment site in GTPS involves identifying the tender or painful area over the greater trochanter using surface anatomical landmarks and palpation. Imaging techniques, such as ultrasound or MRI, may be employed to confirm the diagnosis and pinpoint the exact location of the pain. Care is taken to avoid vital structures like blood vessels and nerves during treatment (source: Royal College of Radiologists, UK).
.jpeg?w=1420&h=800)
Treatment Parameters
When utilizing ESWT for GTPS, the energy flux density and number of impulses are tailored to the individual patient's needs. These parameters may differ based on pain severity, duration of symptoms, and the patient's treatment response. Treatments are usually spaced a few days apart, and a course of treatment may consist of multiple sessions. The efficacy and safety of ESWT for GTPS have been demonstrated in clinical studies, reporting improvements in pain levels, functional outcomes, and quality of life (source: Cochrane Database of Systematic Reviews).
.jpeg?w=1420&h=800)
Treatment Outcome
The effectiveness of ESWT for GTPS varies among patients, but studies have consistently shown positive outcomes. The success rate of ESWT for GTPS can be comparable to other non-invasive treatment options, such as physical therapy, medication, or injections. Some patients experience significant relief from their symptoms, while others may require additional treatments or alternative therapies. The treatment response may vary based on the underlying cause of the pain, individual patient characteristics, and the severity and duration of symptoms. In summary, ESWT provides a non-invasive treatment option for GTPS with proven efficacy and safety in clinical practice, as supported by multiple authoritative sources and clinical studies (source: National Institutes of Health (NIH) and Cochrane Database of Systematic Reviews).
Treatment Steps
Clinical Diagnosis
Conditions I Disease Duration I Exclude Contraindications
Locate Pain Points
Palpation I X-ray I Ultrasound I MRI I Anatomical Landmarks
Set Parameters
Patient Positioning I Energy I Pressure I Frequency I Number of Treatments
SWT TREATMENT
Apply Coupling Agent on Treatment Area I Assess Pain Tolerance
Clean Up End
Remove Coupling Agent I Probe Alcohol Disinfection
Treatment Techniques
-
Rotation/Semi-Static TechniquePerformed at tender points and trigger points, generally not exceeding 1,500 impulses. -
Application/Dynamic TechniqueAround the tender points or surrounding soft tissue, approximately 500 impulses.
Contraindications：
①. Patients with hemorrhagic disorders or coagulation dysfunction;
②. Local and adjacent areas with thrombosis;
③. Patients with severe cognitive impairments or mental illnesses;
④. Local areas with pacemakers;
⑤. Local areas with tumors;
⑥. Lower abdominal region of pregnant women;
⑦. Patients with ruptured or severely injured tendons and fasciae, as well as areas with the brain, spinal cord, large blood vessels, and critical nerve trunks;
⑧. Abdominal organs (especially lung tissue);
⑨. Patients with bone defects greater than 2 centimeters;
⑩. Patients with joint fluid leakage;
⑪. Pediatric patients with growing pains
* Conditions deemed unsuitable by physicians.
Adverse Reactions:
① Local hematoma, ecchymosis, and petechiae at the treatment site;
② Temporary intensification of pain at the treatment site within a short period;
③ Local numbness, needle sensation, and hypoesthesia at the treatment site;
④ High-energy extracorporeal shockwave therapy may cause local nerve and vascular damage;
* These adverse reactions generally resolve within 1 week and do not require special treatment.
② Temporary intensification of pain at the treatment site within a short period;
③ Local numbness, needle sensation, and hypoesthesia at the treatment site;
④ High-energy extracorporeal shockwave therapy may cause local nerve and vascular damage;
* These adverse reactions generally resolve within 1 week and do not require special treatment.
Disclaimer: Content Related to PerVitaShockNavi™ Operational Guidelines
The content related to the PerVitaShockNavi™ Operational Guidelines is solely for reference purposes. Specific operations should be carried out under the guidance and supervision of a professional doctor. Users are advised to consult with a healthcare professional before using any of the procedures or treatments outlined in these guidelines. By accessing and using this information, you acknowledge and agree to hold harmless the providers of this information from any liability arising from the use or misuse of the guidelines.